Skip to content
Evigrade
CriticalSecond-generation systemic triazole antifungal×Antiepileptics. Barbiturates

Updated · Methodology

Mechanism

Phenobarbital strongly induces drug-metabolising enzymes (cytochromes P450 and the glucuronidation enzymes UGT) and the transporter P-gp (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). CYP3A4 and CYP3A5 metabolise isavuconazole, followed by UGT. The European isavuconazole SmPC lists phenobarbital among strong CYP3A4/5 inducers that may markedly lower isavuconazole levels (isavuconazole SmPC, European Medicines Agency, EMA). The two drugs have not been studied together, and there are no figures for this pair. For reference, rifampicin, another strong inducer, reduced isavuconazole exposure (area under the curve, AUC) by 90% (EMA), and by 97% according to the US label (isavuconazole label, US Food and Drug Administration, FDA). The documents do not describe any effect of isavuconazole on phenobarbital levels.

Symptoms

Phenobarbital may markedly lower isavuconazole levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). According to the phenobarbital SmPC, when phenobarbital speeds up the metabolism of another drug, the levels of that drug fall and its effect may weaken (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). For isavuconazole, this means the antifungal effect may be weaker than needed. The size of the effect has not been measured for this pair.

Management

The combination is contraindicated: the European isavuconazole SmPC lists phenobarbital among strong CYP3A4/5 inducers, and the US label contraindicates long-acting barbiturates (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and isavuconazole label, US Food and Drug Administration, FDA). According to its own SmPC, oral phenobarbital is a long-acting barbiturate (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The phenobarbital SmPC does not name isavuconazole but warns that its potent enzyme induction can cause clinically relevant interactions with many groups of drugs (AEMPS). Do not stop phenobarbital abruptly: taper the dose gradually. Abrupt withdrawal after long-term use in a person dependent on the drug can cause withdrawal symptoms, including delirium, seizures and possibly death (AEMPS). No document gives a waiting time between stopping phenobarbital and starting isavuconazole. The half-life of phenobarbital in adults is 50–140 hours and longer in older people and in renal or hepatic impairment (AEMPS). The mean half-life of isavuconazole is 130 hours (FDA). With isavuconazole, evaluate liver tests at the start and during treatment (FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Isavuconazole

Other interactions with Phenobarbital